AbbVie Inc. Common Stock (ABBV)
Stock · NYSE · Health Care
$285.42as of 10/16/2026
Price chart
Active signals
ABBV Signal Track Record
How signals performed across all stocks →What ABBV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +0.2% | 55% | September 4, 2026 |
| 200-Day Moving Average TouchActive now | 31 | +3.6% | 61% | June 18, 2026 |
| Bollinger Band Breakout | 21 | +4.1% | 67% | October 7, 2026 |
| Bollinger Band Breakdown | 21 | +3.2% | 62% | April 22, 2026 |
| Any 20-session window (baseline) | +1.7% | 61% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 57,000
- Website
- www.abbvie.com/
Fundamentals
- 1-day range
- $282.82$291.33
- Market cap
- $430.95B
- P/E (trailing)
- 79.39
- P/E (forward)
- 17.48
- EPS (trailing)
- $3.56
- Dividend yield
- 4.47%
- Beta
- 0.20
- Avg. volume
- 4.86M
- Ex-dividend date
- October 15, 2026
- Dividend pay date
- November 16, 2026
How AbbVie Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 20, 2026 · via SEC EDGAR / Finnhub
Forecasts
28 analyst ratings
AbbVie Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ABBVAbbVie Inc. Common Stock$285.42▲ 0.71%Market cap $430.95BP/E 79.39$190.75$285.4
- MRKMerck & Company Inc. Common Stock (new)$145.95▲ 0.52%Market cap $317.05BP/E 112.60$82.01$156.92
- NVSNovartis AG Common Stock$150.62▲ 0.16%Market cap $294.26BP/E 21.21$97.05$132.68
- AZNAstraZeneca PLC Ordinary Shares$165.41▼ 0.76%Market cap $249.78BP/E 24.19$11,404$15,730
- JNJJohnson & Johnson Common Stock$255.56▲ 0.90%Market cap $619.30BP/E 38.77$184.66$281.07
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABBV AbbVie Inc. Common Stock | $430.95B | 79.39 | $285.42 | ▲ 0.71% | $190.75$285.4 |
| MRK Merck & Company Inc. Common Stock (new) | $317.05B | 112.60 | $145.95 | ▲ 0.52% | $82.01$156.92 |
| NVS Novartis AG Common Stock | $294.26B | 21.21 | $150.62 | ▲ 0.16% | $97.05$132.68 |
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 24.19 | $165.41 | ▼ 0.76% | $11,404$15,730 |
| JNJ Johnson & Johnson Common Stock | $619.30B | 38.77 | $255.56 | ▲ 0.90% | $184.66$281.07 |
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This 3-Stock Roth Portfolio Pays $25,849 a Year Without a Federal Tax BillYahoo · 10/3/2026
- 5 High-Yield Dividend Stocks to Buy for October Income with Cash Flow to SpareYahoo · 10/3/2026
- AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.Yahoo · 10/3/2026
- How to Create a Million-Dollar Stock PortfolioYahoo · 10/2/2026
- How Much Does a 58-Year-Old Need Invested to Replace a $160,000 Salary With Dividends?Yahoo · 10/2/2026
- AbbVie To Participate In Federal 340b Rebate Model PilotBenzinga · 10/2/2026
- Prediction: Eli Lilly Could Be the Next $2 Trillion DrugmakerYahoo · 10/2/2026
- Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?Yahoo · 10/2/2026
Insider Activity
Insider Actions →- Susan E. Quaggin · September 30, 2026 · Grant59 @ $261.59
- Edward J. Rapp · September 30, 2026 · Grant129 @ $261.59
- Nicholas Donoghoe · August 14, 2026 · Option Exercise32.7K @ $79.02
- Nicholas Donoghoe · August 14, 2026 · Sale32.7K @ $250
- Susan E. Quaggin · June 30, 2026 · Grant62 @ $251.64
- Edward J. Rapp · June 30, 2026 · Grant134 @ $251.64
- Susan E. Quaggin · May 8, 2026 · Grant1.1K
- Jennifer L. Davis · May 8, 2026 · Grant1.1K
- Melody B. Meyer · May 8, 2026 · Grant1.1K
- William H.l. Burnside · May 8, 2026 · Grant1.1K
- Brett J. Hart · May 8, 2026 · Grant1.1K
- Rebecca B. Roberts · May 8, 2026 · Grant1.1K
- Thomas C. Freyman · May 8, 2026 · Grant1.1K
- Frederick H. Waddell · May 8, 2026 · Grant1.1K
- Thomas J. Falk · May 8, 2026 · Grant1.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.19B
- Total value held
- $248.47B
- Institutional holders
- 4004
- Unknown150.75M
- Unknown114.88M
- Unknown81.22M
- Unknown46.74M
- Unknown38.02M
- Unknown31.25M
- Unknown23.94M
- Unknown21.76M
- Unknown21.21M
- Unknown16.44M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AbbVie Gains from Oncology Trial News and Dividend Appeal
AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.
AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.